According to a phase III study, the antibody-drug conjugate inotuzumab ozogamicin is more likely to induce complete remissions, with full or incomplete hematologic recovery, in patients with relapsed or refractory acute lymphocytic leukemia. Data from a phase I study of another antibody-drug conjugate, vadastuximab talirine, demonstrates that it is safe and effective against acute myeloid leuke...

et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chron...

A method is proposed for measuring the cytocidal effect of L-asparaginase on leukemic blood cells as a possible means of screening patients for L-asparaginase therapy. On the average, L-asparaginase was more toxic to blood lymphocytes from patients with chronic lymphocytic leukemia than to lymphocytes from normal blood. A positive sensitivity test was defined as one in which 65% of lymphocytes ...

Idelalisib is a novel treatment option for patients with chronic lymphocytic leukemia. A rare, but, fatal complication of using Idelalsib drug induced pneumonitis. This article presents case pneumonitis in patient leukemia along brief discussion management plan.

3. Mattsson J, Uzunel M, Remberger M, et al. Minimal residual disease is common after allogeneic stem-cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host-disease. Leukemia. 2000;14:247-254. 4. Mehta J, Powles R, Singhal S, Iveson T, Treleaven J, Catovsky D. Clinical and hematological response of chronic lymphocytic leukemia and pr...

T HE SENSITIVITY OF LYMPHOCYTES to irradiation provides a rationale for the use of extracorporeal irradiation (ECI ) of the circulating blood to destroy lymphocytes selectively. Since 1962, ECI has been used in various studies, including investigations of lymphocyte physiology and prolongation of allogeneic skin graft survival in calves. These studies1 established the basic feasibility and effe...

In an attempt to lay a sound foundation for understand ing the therapeutic effectiveness of glucocorticoids in the treatment of hematological cancers, we have studied glucocorticoid receptors and sensitivity to glucocorticoids in vitro in the malignant cells from 56 patients with leuke mia and lymphoma and in peripheral lymphocytes from normal donors. In contrast to several previous studies in ...